Bisphosphonates-drugs used for the treatment of osteoporosis such as Fosamax, Reclast, Boniva, Novartis, and Actonel-have received both positive and negative publicity over the past decade. They have a proven record of reducing the risk of fractures among people with osteoporosis, but there are also studies that associate the drugs with fractures and reports that they may lose their effectiveness after a period of time. Credible studies, according to the March 2010 issue of British Journal of Medical Practitioners, found that bisphosphonates might cause "atypical" fractures of the femur (the bone that connects the hip to the knee).
To continue reading this article or issue you must be a paid subscriber.
Sign in
